Age Regulated Macular Degeneration, or AMD as it’s also known, is a common eye condition and the leading form of central vision loss in the UK, currently affecting more than 600,000 people. By 2020, it’s predicted that 700,000 people will have late stage AMD in the UK, making it a fast growing area in healthcare market research.

AMD develops when the macula, a small spot near the centre of the retina that is required for sharp, clear vision, is damaged. In some people, AMD advances so slowly that vision loss doesn’t occur for a long time, whereas in others it progresses quickly and may lead to a loss of vision in one or both eyes.